n
a
v
Portfolio
Genetics
AmplideX® mPCR FMR1 Kit
AmplideX® PCR/CE FMR1 Kit
AmplideX® FMR1 Controls
Xpansion Interpreter®
AmplideX® PCR/CE
SMN1/2
Plus Kit
AmplideX® PCR/CE
CFTR
Kit
AmplideX® PCR/CE C9orf72 Kit
AmplideX® PCR/CE
DMPK
Kit
AmplideX® PCR/CE
HTT
Kit
AmplideX® TRIO
Oncology
QuantideX® qPCR BCR-ABL IS Kit
QuantideX® qPCR BCR-ABL minor Kit
QuantideX® qPCR
ESR1
exoMutation Kit [Coming Soon]
QuantideX® qPCR PML-RARA Kit* [Coming Soon]
MolecularDx Controls
Catalog of Armored Products
SARS CoV-2 Controls
Made-To-Order Armored and Nucleic Acid
Molecular Assay Reagents
Custom & Companion Diagnostics
Partnered R&D
CAP-Accredited CLIA Lab
CTA Testing Site
Validated Platforms & Assays
Companion Diagnostics
Enabling Technologies
Assay Chemistries
Bioinformatics
Product Development Process
Resources
Publications
Articles
Whitepapers
Posters
Disease Information
Fragile X Syndrome
Dementia
Chronic Myeloid Leukemia (CML)
Other Resources
Videos
Carrier Screening Guide
Safety Data Sheets
Sales Contacts
Our Culture
Employee Spotlights
Culture & Heritage
Sales Contacts
Contact
EMEA
About
Leadership Team
Culture and Heritage
News
Upcoming Events
Business Development
Careers
Search
New Horizons for AmplideX® Technology: Portfolio Expansions to New High Complexity Targets & Beyond (AMP 2018)
Home
New Horizons for AmplideX® Technology: Portfolio Expansions to New High Complexity Targets & Beyond (AMP 2018)
New Horizons for AmplideX® Technology: Portfolio Expansions to New High Complexity Targets & Beyond (AMP 2018)
New Horizons for AmplideX® Technology: Portfolio Expansions to New High Complexity Targets & Beyond (AMP 2018)
December 11, 2018
View Asuragen’s AMP 2018 Corporate Workshop about our AmplideX technology.
Back To
Top